Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 651 - 700 out of 3,730

Document Document Title
WO/2010/115751A2
The invention relates to compounds of formula I: wherein R1, R2, Ra, Rb, W, Q and S have the meanings given in claim 1. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis.  
WO/2010/112461A1
The invention relates to compounds of formula (I); wherein R1, R2, Ra, Rb, W, Q and S have the meanings given in claim 1. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis.  
WO/2010/107984A1
The present disclosure provides novel deuterated alpha-(N-sulfonamido)acetamide compounds, their pharmaceutical composition, processes thereof and a method for the treatment of Alzheimer's disease, head trauma, traumatic brain injury, an...  
WO/2010/105179A2
The present invention is directed to a compound represented by the following structural formula or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions and method of use of the compounds are also described.  
WO/2010/097372A1
The invention relates to the compounds of the general formula (I) wherein n, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and X are defined as described below, to enantiomers thereof, to diastereomers thereof, to mixtures and salts there...  
WO/2010/090304A1
Disclosed is an excellent agent for treatment or prevention of dementia, schizophrenia and the like, which has a serotonin 5-HT5A receptor modulating activity. An acylguanidine derivative represented by formula (I), wherein guanidine is ...  
WO/2010/086551A1
The invention relates to compounds of the formula (I) either (i) in the state of a base or an acid addition salt, or (ii) in the state of an acid or a base addition salt, as well as to a method for preparing same and to the therapeutic a...  
WO/2010/087430A1
An N-acyl anthranilic acid derivative represented by general formula (I) or a salt thereof is useful for prevention or treatment of diseases associated with excessive production of collagen. (In the formula, R1 represents a carboxyl grou...  
WO/2010/081877A1
The present invention relates to nitric oxide furoxan derivative compounds which showed to be active in the treatment of tumors. In addition, they may be used as adjuvants in cancer immunotherapy.  
WO/2010/081488A1
The present invention relates to nitric oxide furoxan derivative compounds which showed to be active in the treatment of tumors. In addition, they may be used as vaccines against tumors.  
WO/2010/083404A2
Provided herein are compounds and compositions for interfering with the association of Myc and Max. These compounds and compositions are useful in methods for inhibiting growth or proliferation of a cell. Methods of inhibiting growth or ...  
WO/2010/070343A1
DGAT-1 inhibitor compounds of formula (I) and pharmaceutically-acceptable salts thereof are described, together with pharmaceutical compositions, processes for making them and their use in treating, for example, obesity (I) wherein n is ...  
WO/2010/066380A1
This invention relates to novel compounds suitable for labeling by positron emitting isotopes, such as 18F, 11C, 13N and 15O, through appropriate labeling reagents, such as 18F reagents and methods of preparing such a compound, compositi...  
WO/2010/066682A1
The present invention is directed to novel compounds of formula (I) and their use in treating metabolic diseases.  
WO/2010/050779A1
Provided are novel organic electroluminescent compounds, and organic electroluminescent devices and organic solar cells comprising the same. The organic electroluminescent compounds according to the present invention exhibit high luminou...  
WO/2010/047400A1
A compound represented by formula (1). (In the formula, Ar represents an optionally substituted aromatic hydrocarbon group having 6-20 carbon atoms; Ar' represents an optionally substituted aromatic hydrocarbon group having 6-20 carbon a...  
WO/2010/045258A2
The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula IA, IB, I'A or I'B, where the definitions of the variables are provided herein. The pres...  
WO/2010/041748A1
Disclosed is a prophylactic or therapeutic agent for diabetes, diabetic complications, insulin resistance syndrome, metabolic syndrome, hyperglycemia, dyslipidemia, atherosclerosis, heart failure, cardiomyopathy, myocardial ischemia, cer...  
WO/2010/023448A1
The present invention provides a compound of formula (I) or its salts or pharmaceutically acceptable derivatives thereof wherein; X1 is selected from a group consisting of CH2, C(=O), C(=NH), NC(=O), R1 is selected from the group consist...  
WO/2010/020305A1
The invention relates to novel oxadiazole derivatives of formula (I) wherein R, R', Y, X1, X2 and X3 have the designations cited in claim 1. Said derivatives are kinase inhibitors and can be used to treat illnesses and complaints such as...  
WO/2010/019097A1
The invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is a selected muscarinic receptor antagonist, and a second active ingredient which is selected from a phosphodiesterase inhibi...  
WO/2010/018352A1
The invention provides named compounds of formula (I), pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions and their use in in the treatment of diseases where enhanced M3 receptor activati...  
WO/2010/019098A1
The invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is a selected muscarinic receptor antagonist selected, and a second active ingredient which is a β2-adrenoceptor agonist, of ...  
WO/2010/019772A2
The invention provides 1,2,5-oxadiazole-containing compounds of Formula (I), wherein R1, A, and R2 are as defined herein, that are useful in treating schistosomiasis. The invention also provides a composition comprising a pharmaceuticall...  
WO/2009/013360A9
The invention relates to novel fluorescent derivatives of polyamines having a benzoxadiazole group, to a method for preparing the same and to the use thereof as diagnosis tools for emphasising the polyamine transport system in cancerous ...  
WO/2010/012442A2
The present invention relates to a novel benzenedicarboxamide derivative and the use thereof as an insecticide having the formula (I) wherein the chemical groups W1 to W9, and R1 to R3 are as defined herein.  
WO/2010/009508A1
A compound of Formula (A) wherein Z is an aryl, substituted aryl, heteroaryl, or substituted heteroaryl, wherein the heteroaryl or substituted heteroaryl connected to a 2,4-dinito-6-(trifluoromethyl)phenyl ring via a carbon-carbon bond.  
WO/2010/005958A2
The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and ...  
WO/2010/000019A1
This invention discloses compositions and methods for inducing, promoting or otherwise facilitating pain relief. More particularly, the present invention discloses the use of sub-normovasodilatory doses of furoxan-containing nitric oxide...  
WO/2010/000372A2
The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/...  
WO/2009/101082A9
The present invention relates to the use of substituted sulfonic acid amide compounds of formula I, wherein Ra, n, Het, A, Y and D are as defined in the claims and the N-oxides and the salts thereof for combating phytopathogenic harmful ...  
WO/2009/148452A1
The invention relates to 1,2,4 oxadiazole compounds and analogs thereof, represented by formula (II), and compositions and methods of use thereof.  
WO/2009/071519A9
The present invention relates to novel oxadiazole derivatives as nAChR agonists having pharmacological activity, processes for their preparation, compositions containing them and their use in the treatment of neurological, psychiatric di...  
WO/2009/146343A1
The present invention relates to novel amyloid binding compounds and methods for measuring effects of the compounds, by measuring changes of amyloid plaque level in living patients. More specifically, the present invention relates to a m...  
WO/2009/140089A2
Compounds which modulate the CB2 receptor are disclosed. Compounds according to the invention bind to and are agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally use...  
WO/2009/137657A1
The disclosure provides compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their uses in inhibiting β-amyloid peptide ( β-AP) production.  
WO/2009/137251A2
The present invention provides cysteine and cystine bioisosteres for the treatment of schizophrenia and drug addiction. The invention further encompasses pharmaceutical compositions containing such bioisosteres and methods of using the b...  
WO/2009/131954A2
The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administerin...  
WO/2009/131090A1
Disclosed are: a novel compound which can act as an S1P1 receptor agonist, namely a novel compound which can cause the lymphocyte sequestration in a secondary lymphoid tissue to exhibit an immunosuppressing activity; and a pharmaceutical...  
WO/2009/127723A1
The invention relates to substituted arylsulphonylglycine derivatives of general formula (I) wherein the groups Ra to Rf, A and Z are defined as in the specification and claims, which are suitable for preparing a pharmaceutical compositi...  
WO/2009/125853A1
Disclosed is a homocysteine synthase inhibitor which is useful for the prevention or treatment of a disease associated with homocysteine synthase. Specifically disclosed is a compound represented by general formula (I) [wherein each symb...  
WO/2009/123316A1
Disclosed is an sGC activator, particularly a compound which is useful for the prevention or treatment of diseases including hypertension, ischemic heart diseases, heart failure, kidney diseases, arteriosclerotic diseases, atrial fibrill...  
WO/2009/117421A2
The present invention relates to compounds and methods which may be useful as inhibitors of GPR119 for the treatment or prevention of metabolic, cardiovascular, and metabolic diseases.  
WO/2009/109904A1
The invention relates to novel aminomethyl benzene derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. (I) wherein A represents one of the groups ...  
WO/2009/105214A2
This invention provides compounds of formulas H, Ia, H, and or salts thereof, pharmaceutical compositions comprising a compound of formulas H, Ia, H and a pharmaceutically acceptable excipient, methods of modulating the androgen receptor...  
WO/2009/086277A1
Tetrasubstituted benzenes that act as modulators of gamma secretase and their use in the treatment of one or more symptoms of treating neurodegenerative disorders, e.g., Alzheimer's disease, are described.  
WO/2009/084970A1
The present invention relates to compounds having a 5-O-substituted 3-N-phenyl-1,3,4-oxadiazolone structural unit which have unexpectedly high level of inhibition of FAAH (fatty acid amide hydrolase). (I)  
WO/2009/082347A1
The invention provides compounds of formula (I) wherein R1,R3,L1,L2,G1,G2, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with pro...  
WO/2009/081891A1
Disclosed is a compound represented by the general formula (I), which has a strong COMT inhibitory effect, or a pharmacologically acceptable salt thereof. Also disclosed are a pharmaceutical composition containing the compound or a pharm...  
WO/2009/080725A1
The present application discloses oxadiazole based compounds of Formula (I) active on sphingosine-1-phosphate (S1P) in particular useful to treat lupus erythematosus. A is phenyl or a 5 or 6-membered heteroaryl ring; R1 is up to two subs...  

Matches 651 - 700 out of 3,730